Vir Biotechnology, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Vir Biotechnology, Inc. (VIR) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$8.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $8.39M.
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$17.22M, a 195.62% decline year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $10.10M.
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$11.62M, a 160.28% decline year-over-year.
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$9.51M.
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$64.02M.
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$358.84M.
- Vir Biotechnology, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$15.51M, a 126.52% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$8.83M 10-Q · filed 2026-08-05 | $1.27M derived: sum of 3 quarters · filed 2026-08-05 | -$10.34M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$17.22M 10-Q · filed 2026-05-07 | -$7.12M derived: sum of 2 quarters · filed 2026-05-07 | -$18.73M derived: sum of 3 quarters · filed 2026-05-07 | -$44.74M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$1.51M derived: sum of 2 quarters · filed 2026-02-23 | -$27.52M derived: sum of 3 quarters · filed 2026-08-05 | -$9.51M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$11.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$37.63M derived: sum of 2 quarters · filed 2026-08-05 | -$19.61M 10-Q · filed 2025-11-05 | -$68.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$26.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$8.00M 10-Q · filed 2026-08-05 | -$5.46M 10-Q · filed 2025-08-06 | -$56.49M derived: sum of 3 quarters · filed 2026-08-05 | -$37.22M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $18.01M 10-Q · filed 2026-05-07 | $18.73M 10-Q · filed 2025-05-08 | -$30.48M derived: sum of 2 quarters · filed 2026-05-07 | -$11.21M derived: sum of 3 quarters · filed 2026-05-07 | -$16.00M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$48.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$29.22M derived: sum of 2 quarters · filed 2026-02-23 | -$34.02M derived: sum of 3 quarters · filed 2026-02-23 | -$64.02M 10-K · filed 2026-02-23 | -$10.29M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $19.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $14.47M derived: sum of 2 quarters · filed 2025-11-05 | -$15.53M 10-Q · filed 2025-11-05 | -$15.51M 10-Q · filed 2024-11-04 | -$57.45M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | -$4.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$34.80M 10-Q · filed 2025-08-06 | -$34.77M 10-Q · filed 2024-08-01 | -$76.72M derived: sum of 3 quarters · filed 2026-02-23 | -$123.88M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-03-31 | -$30.00M 10-Q · filed 2025-05-08 | -$71.93M derived: sum of 2 quarters · filed 2026-02-23 | -$119.08M derived: sum of 3 quarters · filed 2026-02-23 | -$384.81M derived: sum of 4 quarters · filed 2026-02-23 | ||||
| 2023-12-31 | -$41.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$89.08M derived: sum of 2 quarters · filed 2026-02-23 | -$354.81M derived: sum of 3 quarters · filed 2026-02-23 | -$358.84M 10-K · filed 2026-02-23 | -$356.50M 10-K · filed 2024-02-26 | |||
| 2023-09-30 | -$47.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$312.88M derived: sum of 2 quarters · filed 2024-11-04 | -$316.92M 10-Q · filed 2024-11-04 | -$397.57M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | -$265.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$269.76M 10-Q · filed 2024-08-01 | -$350.42M derived: sum of 3 quarters · filed 2025-02-27 | -$430.66M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$4.04M 10-Q · filed 2024-05-03 | -$84.69M derived: sum of 2 quarters · filed 2025-02-27 | -$164.93M derived: sum of 3 quarters · filed 2025-02-27 | -$453.11M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$80.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$160.89M derived: sum of 2 quarters · filed 2025-02-27 | -$449.07M derived: sum of 3 quarters · filed 2025-02-27 | -$15.51M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$80.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$368.41M derived: sum of 2 quarters · filed 2023-11-03 | $65.14M 10-Q · filed 2023-11-03 | $137.13M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | -$288.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $145.38M 10-Q · filed 2023-08-04 | $217.37M derived: sum of 3 quarters · filed 2024-02-26 | $226.17M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $433.56M 10-Q · filed 2023-05-08 | $505.54M derived: sum of 2 quarters · filed 2024-02-26 | $514.34M derived: sum of 3 quarters · filed 2024-02-26 | $510.88M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $71.99M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $80.78M derived: sum of 2 quarters · filed 2024-02-26 | $77.33M derived: sum of 3 quarters · filed 2024-02-26 | $58.50M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $8.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.34M derived: sum of 2 quarters · filed 2022-11-03 | -$13.49M 10-Q · filed 2022-11-03 | $19.94M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$3.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$22.29M 10-Q · filed 2022-08-09 | $11.14M derived: sum of 3 quarters · filed 2023-02-28 | $17.54M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$18.83M 10-Q · filed 2022-05-05 | $14.60M derived: sum of 2 quarters · filed 2023-02-28 | $21.00M derived: sum of 3 quarters · filed 2023-02-28 | $37.99M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $33.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $39.82M derived: sum of 2 quarters · filed 2023-02-28 | $56.82M derived: sum of 3 quarters · filed 2023-02-28 | $46.61M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $6.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $23.39M derived: sum of 2 quarters · filed 2021-11-04 | $13.18M 10-Q · filed 2021-11-04 | $17.72M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $6.79M 10-Q · filed 2021-08-05 | $11.32M derived: sum of 3 quarters · filed 2022-02-28 | $15.31M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | -$10.20M 10-Q · filed 2021-05-06 | -$5.67M derived: sum of 2 quarters · filed 2022-02-28 | -$1.68M derived: sum of 3 quarters · filed 2022-02-28 | $1.96M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $8.52M derived: sum of 2 quarters · filed 2022-02-28 | $12.17M derived: sum of 3 quarters · filed 2022-02-28 | $10.21M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $7.63M derived: sum of 2 quarters · filed 2020-11-10 | $5.68M 10-Q · filed 2020-11-10 | $6.78M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $3.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $1.69M 10-Q · filed 2020-08-11 | $2.80M derived: sum of 3 quarters · filed 2021-02-25 | |||||
| 2019-03-31 | -$1.96M 10-Q · filed 2020-05-12 | -$852.00K derived: sum of 2 quarters · filed 2021-02-25 | ||||||
| 2018-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $7.17M 10-K · filed 2021-02-25 | ||||||
| 2018-09-30 | $6.07M 10-Q · filed 2019-11-19 | |||||||
| 2017-12-31 | $4.81M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |